Equity Details
Price & Market Data
Price: $2.10
Daily Change: $0.00 / 0.00%
Daily Range: $2.02 - $2.14
Market Cap: $238,235,904
Daily Volume: 502,135
Performance Metrics
1 Week: -13.45%
1 Month: -14.17%
3 Months: -39.77%
6 Months: -48.50%
1 Year: 118.0%
YTD: -48.24%
About NovaBridge Biosciences (NBP)
Analyze the market position of NovaBridge Biosciences (NBP). With a current price of 2.10, the stock exhibits a $0.00 / 0.00% daily trend. A market capitalization of 238,235,904 indicates its scale. Discover its performance over 1-month (-14.17%) and 3-month (-39.77%) periods.
Company Details
Employees: 30
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.